Janssen To Discontinue Internal Development Of Cidara Therapeutics-Partnered Influenza Candidate
Portfolio Pulse from Vandana Singh
Janssen Pharmaceuticals, a part of Johnson & Johnson, has announced its intention to discontinue the internal development of most of its infectious disease pipeline, including JNJ-0953 (CD388), a program for the prevention of influenza A and B, which is under an exclusive worldwide license and collaboration agreement with Cidara Therapeutics. However, Janssen has not informed Cidara of any intention to terminate the agreement. Cidara continues to collaborate with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the collaboration agreement.
July 21, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cidara Therapeutics' influenza program, CD388, may face uncertainty due to Janssen's decision to discontinue its internal development. However, the collaboration agreement remains intact and Cidara will be reimbursed for ongoing development activities.
Janssen's decision to discontinue the internal development of most of its infectious disease pipeline, including CD388, could potentially impact Cidara's operations and future prospects. However, the fact that the collaboration agreement remains intact and that Cidara will be reimbursed for ongoing development activities mitigates some of the potential negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Janssen Pharmaceuticals, a part of Johnson & Johnson, has decided to discontinue the internal development of most of its infectious disease pipeline, including a program partnered with Cidara Therapeutics. This could potentially lead to a shift in Janssen's R&D focus.
Janssen's decision to discontinue the internal development of most of its infectious disease pipeline could potentially lead to a shift in its R&D focus. However, the overall impact on Johnson & Johnson is likely to be limited given the company's diverse portfolio.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 80